Notes
CD26 antigen
Reference
Fralick M, et al. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. New England Journal of Medicine 376: 2300-2302, 8 Jun 2017. Available from: URL: http://dx.doi.org/10.1056/NEJMc1701990
Rights and permissions
About this article
Cite this article
SGLT2 inhibitors increase risk of diabetic ketoacidosis. Reactions Weekly 1656, 12 (2017). https://doi.org/10.1007/s40278-017-31342-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-31342-z